G84E mutation in HOXB13 is firmly associated with prostate cancer risk: A meta-analysis

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1177-1182

  Huang, Hang ^a   Cai, Bing ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

G84E; HOXB13; Meta analysis; Mutation; Prostatic neoplasms

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXB13; UNCLASSIFIED DRUG;

AGE; AGGRESSIVENESS; ARTICLE; CANCER RISK; COMPARATIVE STUDY; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SYSTEMATIC REVIEW;

GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84899068774     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1157-5     Document Type: Article

References (26)

1. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, et al. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate. 2010;70:1729-38.
2. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43:785-91.
3. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141-9.
4. Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol. 2012. doi:10.1016/j.eururo.2012.07.027.
5. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2013;132:5-14.
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
7. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12. (Pubitemid 30214957)
8. Handoll HH. Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil. 2006;87:875. (Pubitemid 43767714)
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. (Pubitemid 37088507)
10. Zhu S, Zhang H, Xie L, Chen J, Niu Y. Risk factors and prevention of inguinal hernia after radical prostatectomy: a systematic review and meta-analysis. J Urol. 2013;189:884-90.
11. Stott-Miller M, Karyadi DM, Smith T, Kwon EM, Kolb S, Stanford JL, et al. HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate. 2012. doi:10.1002/pros.22604.
12. Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:1348-53.
13. Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, Benediktsdottir KR, et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet. 2012;44:1326-9.
14. Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst. 2012;104:1260-2.
15. Kluzniak W, Wokolorczyk D, Kashyap A, Jakubowska A, Gronwald J, Huzarski T, et al. The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate. 2013;73:542-8.
16. Chen Z, Greenwood C, Isaacs WB, Foulkes WD, Sun J, Zheng SL, et al. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis. 2013;34:1260-4.
17. Witte JS, Mefford J, Plummer SJ, Liu J, Cheng I, Klein EA, et al. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomarkers Prev. 2013;22:675-80.
18. Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2013;22:452-60.
19. Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, et al. A novel Germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate. 2013;73:169-75.
20. Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development. 2003;130:2061-9. (Pubitemid 36656703)
21. Kondo T, Zakany J, Innis JW, Duboule D. Of fingers, toes and penises. Nature. 1997;390:29.
22. Podlasek CA, Duboule D, Bushman W. Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dyn. 1997;208:454-65. (Pubitemid 27152838)
23. Warot X, Fromental-Ramain C, Fraulob V, Chambon P, Dolle P. Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development. 1997;124:4781-91. (Pubitemid 28014381)
24. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21:224-34.
25. Chen J, Zhu S, Jiang N, Shang Z, Quan C, Niu Y. HoxB3 promotes prostate cancer cell progression by transactivating CDCA3. Cancer Lett. 2012;330:217-24.
26. Klein C, Lohmann K, Ziegler A. The promise and limitations of genome-wide association studies. JAMA. 2012;8:1-2.